BRIEF-Boehringer Ingelheim, Eli Lilly submit NDA to FDA for Empagliflozin, an investigational type 2 diabetes treatment

March 25 (Reuters) - Eli Lilly and Co :

* Boehringer ingelheim and Eli Lilly and Company submit new drug application to

FDA for Empagliflozin, an investigational type 2 diabetes treatment

* Source text * Further company coverage

((Bangalore Newsroom; +1 646 223 8780))

View the original article here